SCM
TSVT

Stonepine Capital Management’s 2seventy bio TSVT Stock Holding History

Stonepine Capital Management’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-300,000
Closed -$882K – 73
2024
Q4 		$882K Buy
300,000
+200,000
+200% +$820K 0.71% 31
2024
Q3 		$472K Hold
100,000
– – 0.3% 32
2024
Q2 		$385K Buy
+100,000
New +$451K 0.35% 22

Other funds holding TSVT

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Stonepine Capital Management's TSVT Position: Q1 2025 in Review

Stonepine Capital Management sold out of 2seventy bio (TSVT) in Q1 2025, closing a stake of 300,000 shares — an estimated $882K sold.

Stonepine Capital Management first reported a position in TSVT in Q2 2024 and held it in 3 quarters. The position peaked at $882K in Q4 2024. 139 funds tracked by Wall St. Rank hold TSVT as of Q1 2025.

  • Stonepine Capital Management reported no remaining 2seventy bio position as of Q1 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 300,000 2seventy bio shares in Q1 2025, an estimated $882K.
  • Stonepine Capital Management first reported a position in 2seventy bio in Q2 2024 and held it in 3 quarters.
  • Stonepine Capital Management's 2seventy bio position peaked at $882K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2025.

Based on Stonepine Capital Management's 13F filing for Q1 2025, filed 14 May 2025.